Recently, a world-renowned expert delegation from the German Cancer Research Center (DKFZ, hereinafter referred to as the German Cancer Research Center) affiliated to Heidelberg University visited China.
The delegation visited and exchanged many top-level oncology medical institutions in China. As the only company, the pan-born children have once again been recognized and praised by international authorities.
Professor Duke Hai, Professor of Duke University and co-founder and chief scientist of the University of Duke, warmly hosted Professor Michael Baumann, Scientific Chairman and CEO of the German Cancer Research Center, Professor Josef Puchta, Executive Director, and Professor Eike Otrom Martin, International Relations Coordinator Professor of the American Academy of Sciences, Director of the Central Nervous System Strategic Alliance of Ludwig Cancer Institute, Professor Webster Cavenee, Chairman and Chief Operating Officer of the American Cancer Research Foundation (NFCR), and Founder and CEO of the Asian Cancer Research Foundation (AFCR) Dr. Ba Sujuan, the two sides actively discussed and exchanged their respective business capabilities, research projects and cooperation in the future.
Experts from the German Cancer Research Center affiliated to the University of Heidelberg visited the pan-son
During the trip to China, the delegation also visited Beijing Tiantan Hospital affiliated to Capital Medical University, Peking University Cancer Hospital, Tianjin Medical University Affiliated Tumor Hospital, Fudan University Affiliated Tumor Hospital, Fudan University Affiliated Huashan Hospital and Shanghai Jiaotong University School of Medicine. Ruijin Hospital.
About the German Cancer Research Center
The German Cancer Research Center is Germany's largest biomedical research institution and is one of the most comprehensive and in-depth research institutions for cancer research in Europe and around the world. In the more than 100 years since the establishment of the German Cancer Research Center, two of the two have been awarded Nobel. Award scientist.
At present, the center has more than 90 departments and research groups, among which scientists through the basic research and scientific research of cancer, in order to make the diagnosis of cancer more accurate, provide better treatment for cancer patients, and is committed to anti-cancer and anti-cancer Effective strategy.
About the birth of a child
As an international company focused on cancer precision medicine , Panson has dual R&D centers in North Carolina and Beijing, China, and has established long-term cooperation with Duke University and Johns Hopkins University, the two leading cancer research centers in the United States. The partnership will help the general population to consolidate the foundation of cancer genomics, introduce international research resources, and accelerate the clinical transformation of new technologies for cancer diagnosis and treatment at home and abroad.
In addition, the company has a multi-disciplinary team of experts, and cooperates with top cancer hospitals and research institutions at home and abroad to publish more than ten research results in world-leading academic journals such as Nature Genetics.
With a deep foundation of cancer genomics and strong scientific research and clinical transformation strength, Panshengzi has attracted many internationally renowned scientific research institutions and association experts to visit and exchange. In the future, the pan-family will continue to bring together the world's top cancer research forces to bring more hope to cancer patients.
Joint replacement is a medical treatment in which an artificial joint is used to replace a painful joint that has lost function.Our joint replacements are divided into Hip Artificial Prosthesis and Total Knee Artificial Prosthesis System.
The artificial femoral stems are also available in a plain type (which requires cement) and a coral type without cement. Indications for joint replacement include osteonecrosis, irreducible comminted fractures and dislocations, osteoarthropathy with pain and mobility disorders, rheumatoid arthritis with rigidity or difficulty in mobility, and bone tumors. Complications of replacement include loosening of the prosthesis, wear or fracture, deep infection, foreign body reaction, and soft tissue calcification that impedes movement.
hip Replacements,Hip Implants,Hip Artificial Prosthesis,Artificial Prosthesis
Jiangsu Aomed Ortho Medical Technology Co.,Ltd , https://www.aomedortho.com